Ticker Symbol: UNCY
Unicycive Therapeutics Inc
$2.74 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001766140
Company Profile
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: unicycive.com
CEO: N/A
Tags:
N/A
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.89
Change:
-$0.02
(
-3.25%)
Days Range: $0.86 - $0.95
Beta: 0.52
52wk. High: $2.87
52wk. Low: $0.40
Ytd. Change 67.10%
50 Day Moving Average: $0.77
200 Day Moving Average: $1.19
Shares Outstanding: 34752221
Valuation
Market Cap: 3.1B
PE Ratio: -0.45
EPS (TTM): -1.98
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A